Katinka Albrecht1, Denis Poddubnyy2, Jan Leipe3, Philipp Sewerin4, Christof Iking-Konert5, Roger Scholz6, Klaus Krüger7. 1. Programme Area of Epidemiology and Health Care Research, German Rheumatism Research Center Berlin, Berlin, Germany. 2. Rheumatology at the Benjamin Franklin Campus-Medical Clinic for Gastroenterology, Infectiology and Rheumatology, Charité University Medicine Berlin, Berlin, Germany. 3. Division of Rheumatology, Department of Medicine V, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. 4. Department of Rheumatology & Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany. 5. Department of Rheumatology, Stadtspital Zürich, Zürich, Switzerland. 6. Orthopaedics and Trauma Surgery, Collm Klinik Oschatz, Oschatz, Germany. 7. Rheumatology Practice Center Munich, St.-Bonifatius-Str. 5, 81541, Munich, Germany. klaus.krueger@med.uni-muenchen.de.
Abstract
BACKGROUND: Prior to surgical interventions physicians and patients with inflammatory rheumatic diseases remain concerned about interrupting or continuing anti-inflammatory medication. For this reason, the German Society for Rheumatology has updated its recommendations from 2014. METHODS: After a systematic literature search including publications up to 31 August 2021, the recommendations on the use of of glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologics (bDMARDs) were revised and recommendations on newer drugs and targeted synthetic (ts)DMARDs were added. RESULTS: The glucocorticoid dose should be reduced to as low as possible 2-3 months before elective surgery (in any case <10 mg/day) but should be kept stable 1-2 weeks before and on the day of surgery. In many cases csDMARDs can be continued, exceptions being a reduction of high methotrexate doses to ≤15 mg/week and wash-out of leflunomide if there is a high risk of infection. Azathioprine, mycophenolate and ciclosporin should be paused 1-2 days prior to surgery. Under bDMARDs surgery can be scheduled for the end of each treatment interval. For major interventions Janus kinase (JAK) inhibitors should be paused for 3-4 days. Apremilast can be continued. If interruption is necessary, treatment should be restarted as soon as possible for all substances, depending on wound healing. CONCLUSION: Whether bDMARDs increase the perioperative risk of infection and the benefits and risks of discontinuation remain unclear based on the currently available evidence. To minimize the risk of a disease relapse under longer treatment pauses, in the updated recommendations the perioperative interruption of bDMARDs was reduced from at least two half-lives to one treatment interval.
BACKGROUND: Prior to surgical interventions physicians and patients with inflammatory rheumatic diseases remain concerned about interrupting or continuing anti-inflammatory medication. For this reason, the German Society for Rheumatology has updated its recommendations from 2014. METHODS: After a systematic literature search including publications up to 31 August 2021, the recommendations on the use of of glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologics (bDMARDs) were revised and recommendations on newer drugs and targeted synthetic (ts)DMARDs were added. RESULTS: The glucocorticoid dose should be reduced to as low as possible 2-3 months before elective surgery (in any case <10 mg/day) but should be kept stable 1-2 weeks before and on the day of surgery. In many cases csDMARDs can be continued, exceptions being a reduction of high methotrexate doses to ≤15 mg/week and wash-out of leflunomide if there is a high risk of infection. Azathioprine, mycophenolate and ciclosporin should be paused 1-2 days prior to surgery. Under bDMARDs surgery can be scheduled for the end of each treatment interval. For major interventions Janus kinase (JAK) inhibitors should be paused for 3-4 days. Apremilast can be continued. If interruption is necessary, treatment should be restarted as soon as possible for all substances, depending on wound healing. CONCLUSION: Whether bDMARDs increase the perioperative risk of infection and the benefits and risks of discontinuation remain unclear based on the currently available evidence. To minimize the risk of a disease relapse under longer treatment pauses, in the updated recommendations the perioperative interruption of bDMARDs was reduced from at least two half-lives to one treatment interval.
Authors: Susan M Goodman; Bryan Springer; Gordon Guyatt; Matthew P Abdel; Vinod Dasa; Michael George; Ora Gewurz-Singer; Jon T Giles; Beverly Johnson; Steve Lee; Lisa A Mandl; Michael A Mont; Peter Sculco; Scott Sporer; Louis Stryker; Marat Turgunbaev; Barry Brause; Antonia F Chen; Jeremy Gililland; Mark Goodman; Arlene Hurley-Rosenblatt; Kyriakos Kirou; Elena Losina; Ronald MacKenzie; Kaleb Michaud; Ted Mikuls; Linda Russell; Alexander Sah; Amy S Miller; Jasvinder A Singh; Adolph Yates Journal: Arthritis Rheumatol Date: 2017-06-16 Impact factor: 10.995
Authors: Michael D George; Joshua F Baker; Kevin L Winthrop; Seth D Goldstein; E Alemao; Lang Chen; Qufei Wu; Fenglong Xie; Jeffrey R Curtis Journal: Ann Rheum Dis Date: 2020-03-24 Impact factor: 19.103
Authors: Bella Mehta; Deanna Jannat-Khah; Mark Alan Fontana; Carine J Moezinia; Carol A Mancuso; Anne R Bass; Vinicius C Antao; Allan Gibofsky; Susan M Goodman; Said Ibrahim Journal: RMD Open Date: 2020-10